US Bancorp
PLRX icon

US Bancorp’s Pliant Therapeutics PLRX Stock Holding History

US Bancorp’s Portfolio PLRX Stock Details PLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-454
Closed -$5.98K – 4326
2024
Q4 		$5.98K Sell
454
-110
-20% -$1.5K ﹤0.01% 3597
2024
Q3 		$6.32K Sell
564
-379
-40% -$4.74K ﹤0.01% 3504
2024
Q2 		$10.1K Sell
943
-761
-45% -$9.81K ﹤0.01% 3297
2024
Q1 		$25.4K Buy
1,704
+825
+94% +$13.6K ﹤0.01% 2999
2023
Q4 		$15.9K Sell
879
-159
-15% -$2.42K ﹤0.01% 3143
2023
Q3 		$18K Sell
1,038
-1,112
-52% -$19.3K ﹤0.01% 2934
2023
Q2 		$39K Buy
2,150
+1,270
+144% +$30.1K ﹤0.01% 2624
2023
Q1 		$23.4K Buy
880
+21
+2% +$598 ﹤0.01% 2910
2022
Q4 		$16.6K Hold
859
– – ﹤0.01% 3084
2022
Q3 		$18K Buy
859
+409
+91% +$7.83K ﹤0.01% 3074
2022
Q2 		$4K Hold
450
– – ﹤0.01% 3662
2022
Q1 		$3K Sell
450
-150
-25% -$1.53K ﹤0.01% 3762
2021
Q4 		$8K Sell
600
-98
-14% -$1.56K ﹤0.01% 3510
2021
Q3 		$12K Buy
698
+98
+16% +$2.08K ﹤0.01% 3365
2021
Q2 		$17K Hold
600
– – ﹤0.01% 3221
2021
Q1 		$24K Buy
+600
New +$19.5K ﹤0.01% 2947

Other funds holding PLRX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

US Bancorp's PLRX Position: Q1 2025 in Review

US Bancorp sold out of Pliant Therapeutics (PLRX) in Q1 2025, closing a stake of 454 shares — an estimated $5.98K sold.

US Bancorp first reported a position in PLRX in Q1 2021 and held it in 16 quarters. The position peaked at $39K in Q2 2023. 140 funds tracked by Wall St. Rank hold PLRX as of Q1 2025.

  • US Bancorp reported no remaining Pliant Therapeutics position as of Q1 2025 after selling out during the quarter.
  • US Bancorp sold 454 Pliant Therapeutics shares in Q1 2025, an estimated $5.98K.
  • US Bancorp first reported a position in Pliant Therapeutics in Q1 2021 and held it in 16 quarters.
  • US Bancorp's Pliant Therapeutics position peaked at $39K in Q2 2023.
  • 140 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q1 2025.

Based on US Bancorp's 13F filing for Q1 2025, filed 8 May 2025.